Neogenomics, Inc.
Could not find a ticker for this position, may be a filing error
A laboratory that focuses exclusively on cancer testing, helping oncologists and pathologists diagnose tumors and choose treatments through genetic and molecular analysis. Founded in 2001 in Fort Myers, Florida, by a pathologist and a healthcare executive, it has grown into one of the largest oncology-focused reference labs in the United States. The name blends "neo" — Greek for "new" — with "genomics," a nod to the modern genetic techniques at its core.
0.25% Convertible Senior Notes due 2028
Granted 105.5K
Granted 99.2K · Bought 40.0K
Granted 164.1K · Bought 36.8K
Granted 168.5K · Bought 5.7K · Sold 22.1K
Granted 23.6K
Granted 15.5K
Granted 123.3K · Sold 38.4K
Granted 46.7K · Bought 7.0K · Sold 16.7K
Granted 46.7K · Bought 4.0K
Granted 46.7K · Bought 5.0K
Granted 46.7K · Bought 10.0K
Granted 46.7K · Bought 4.5K
Granted 30.2K
Granted 17.1K
Granted 23.6K
Granted 23.0K
Granted 5.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Smith Christopher MChief Executive Officer · 5 transactions | +6.5% | 641.6Kas of Feb 2025 | 105.5K | — | — |
| Sherman Jeffrey ScottChief Financial Officer · 15 transactions | +64.4% | 220.0K | 99.2K | 40.0K | — |
| Zook Anthony P.Chief Executive Officer, Director · 7 transactions | — | 209.0K | 164.1K | 36.8K | — |
| Stone WarrenPres & Chief Operating Officer · 26 transactions | +88.1% | 167.8K | 168.5K | 5.7K | 22.1K |
| Hannah Alison L.Director · 2 transactions | +22% | 131.0Kas of Jun 2025 | 23.6K | — | — |
| Harris MelodyChf Ops Off, Pres, Informatics · 6 transactions | +0.2% | 109.8Kas of Feb 2025 | 15.5K | — | — |
| Olivo Alicia CEVP, GC & Business Development · 31 transactions | +128.3% | 93.6K | 123.3K | — | 38.4K |
| Tetrault LYNN A.Director · 7 transactions | — | 93.1K | 46.7K | 7.0K | 16.7K |
| Kanovsky Stephen MDirector · 4 transactions | +204.7% | 75.4K | 46.7K | 4.0K | — |
| Kelly Michael AaronDirector · 4 transactions | — | 72.1K | 46.7K | 5.0K | — |
| Perez David BrianDirector · 4 transactions | — | 67.0K | 46.7K | 10.0K | — |
| Gunn NeilDirector · 4 transactions | — | 51.2K | 46.7K | 4.5K | — |
| Williams FeliciaDirector · 2 transactions | — | 30.2K | 30.2K | — | — |
| Aunan Greg DChief Accounting Officer · 9 transactions | +63.4% | 25.2K | 17.1K | — | — |
| Floegel ElizabethDirector · 2 transactions | — | 23.6Kas of Jun 2025 | 23.6K | — | — |
| Green Marjorie CDirector · 1 transaction | — | 23.0K | 23.0K | — | — |
| Kenny John P.Director · 1 transaction | — | 5.9K | 5.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +35.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.